Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults —Reply

In Reply Noting the differences in anerobic coverage between cefepime and piperacillin-tazobactam, Dr Chanderraj and colleagues inquire how commonly clinicians in our recent ACORN trial elected to co-administer antibiotics with anerobic coverage (eg, metronidazole or clindamycin) to patients in the cefepime group vs the piperacillin-tazobactam group. In the 14 days after enrollment, 564 patients (46.5%) in the cefepime group and 248 patients (19.1%) in the piperacillin-tazobactam group received either metronidazole or clindamycin, of which 535 (44.1%) and 173 (13.3%), respectively, received them during the first 3 days after enrollment. Thus, most patients in the cefepime group did not receive antibiotics that covered anaerobes, and the effects of which on the microbiome and patient outcomes should be examined in future research.
Source: JAMA - Category: General Medicine Source Type: research